Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    bapineuzumab | Phase 3
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Terminated
Has Results
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Bapineuzumab 1.0 m/kg
2 Terminated Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab;   Drug: placebo
3 Terminated Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab;   Drug: placebo
4 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Placebo Control;   Drug: Bapineuzumab 1.0 m/kg
5 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Placebo Control;   Drug: Bapineuzumab 1.0 m/kg
6 Terminated A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
Condition: Alzheimer Disease
Intervention: Drug: Bapineuzumab 0.5 mg/kg
7 Terminated A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Bapineuzumab

Indicates status has not been verified in more than two years